Figure 4.

Cancer vaccine inhibit tumor growth in vivo. (a) Schematic representation of experimental design. Cmah^–/– mice were immunized intraperitoneally (i.p.) with NG^neg or NG^pos (n=10 per group) in the optimized B1W regimen. Mouse serum was sampled on day 0 then weekly (red arrows). On week 7.5, 0.5 × 10⁶ MC38-GFP cells were inoculated subcutaneously (green arrow). (b) Tumor volumes were monitored every other day showing inhibition of tumor growth in the NG^pos vaccine-treated group (mean ±SEM; One-Way ANOVA with Bonferroni posttests, ** p<0.01, *** p<0.001; in NG^pos group, two mice became necrotic on week 10 and were excluded from analysis). (c) Sera samples were then analyzed by sialoglycan microarrays containing diverse sialoglycans, detected with Cy3- labeled anti-mouse IgG. Each line represents the average response of 10 mice per group against all Neu5Gc-glycans. (d) Array response agaisns the 24 individual Neu5Gc-glycans (colored lines).